Effect of age on mortality, hospitalizations and response to digoxin in patients with heart failure: The DIG study

被引:117
作者
Rich, MW
McSherry, F
Williford, WO
Yusuf, S
机构
[1] Washington Univ, Sch Med, Div Cardiovasc, St Louis, MO 63110 USA
[2] Vet Adm Med Ctr, Perry Point, MD USA
[3] Hamilton Gen Hosp, Toronto, ON, Canada
关键词
D O I
10.1016/S0735-1097(01)01442-5
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVES This study was designed to determine the effect of increasing age on mortality, hospitalizations and digoxin side effects in patients with heart failure (HF), and to determine whether the effect of digoxin on clinical outcomes varies as a function of age. BACKGROUND The incidence and prevalence of HF increase with advancing age, but there are limited data on the clinical course and response to specific therapeutic interventions in elderly patients with HF. METHODS The Digitalis Investigation Group (DIG) study was a prospective, randomized clinical trial involving 7,788 patients with HF randomized to digoxin or placebo and followed for an average of 37 months. In the present analysis, patients were stratified into five age categories: < 50 years (n = 841), 50 to 59 years (n = 1,545), 60 to 69 years (n = 2,885), 70 to 79 years (n = 2,092) and greater than or equal to 80 years (n = 425). Interactions between age and the following clinical outcomes were examined: total mortality, all-cause hospitalizations, HF hospitalizations, the composite of HF death or HF hospitalization, hospitalization for suspected digoxin toxicity and withdrawal from therapy because of side effects. RESULTS Increasing age was an independent risk factor for total mortality, all-cause hospitalization, HF hospitalization, HF death or hospital admission, hospitalization for suspected digoxin toxicity and withdrawal from digoxin therapy (all p < 0.001). However, there were no significant interactions between age and digoxin treatment with respect to any of the major clinical end points. CONCLUSIONS Increasing age is associated with progressively worse clinical outcomes in patients with HF. However, the beneficial effects of digoxin in reducing all-cause admissions, HF admissions, and HF death or hospitalization are independent of age. Thus, digoxin remains a useful agent for the adjunctive treatment of HF due to impaired left ventricular systolic function in patients of all ages. (C) 2001 by the American College of Cardiology.
引用
收藏
页码:806 / 813
页数:8
相关论文
共 15 条
[1]  
Abernathy GT, 1996, CONTROL CLIN TRIALS, V17, P77
[2]   IS DIGOXIN REALLY IMPORTANT IN TREATMENT OF COMPENSATED HEART-FAILURE - A PLACEBO-CONTROLLED CROSSOVER STUDY IN PATIENTS WITH SINUS RHYTHM [J].
FLEG, JL ;
GOTTLIEB, SH ;
LAKATTA, EG .
AMERICAN JOURNAL OF MEDICINE, 1982, 73 (02) :244-250
[3]   LACK OF CORRELATION BETWEEN EXERCISE CAPACITY AND INDEXES OF RESTING LEFT-VENTRICULAR PERFORMANCE IN HEART-FAILURE [J].
FRANCIOSA, JA ;
PARK, M ;
LEVINE, TB .
AMERICAN JOURNAL OF CARDIOLOGY, 1981, 47 (01) :33-39
[4]   Predictors of congestive heart failure in the elderly: The cardiovascular health study [J].
Gottdiener, JS ;
Arnold, AM ;
Aurigemma, GP ;
Polak, JF ;
Tracy, RP ;
Kitzman, DW ;
Gardin, JM ;
Rutledge, JE ;
Boineau, RC .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2000, 35 (06) :1628-1637
[5]  
GRAVES EJ, 1992, VITAL HLTH STAT, V13, P1
[6]   EPIDEMIOLOGY OF HEART-FAILURE [J].
KANNEL, WB ;
BELANGER, AJ .
AMERICAN HEART JOURNAL, 1991, 121 (03) :951-957
[7]  
Kitzman Dalane W., 2000, Cardiology Clinics, V18, P597, DOI 10.1016/S0733-8651(05)70164-8
[8]  
OWINGS MF, 1999, VITAL HLTH STAT SERI, V13, P14
[9]   WITHDRAWAL OF DIGOXIN FROM PATIENTS WITH CHRONIC HEART-FAILURE TREATED WITH ANGIOTENSIN-CONVERTING ENZYME-INHIBITORS [J].
PACKER, M ;
GHEORGHIADE, M ;
YOUNG, JB ;
COSTANTINI, PJ ;
ADAMS, KF ;
CODY, RJ ;
SMITH, LK ;
VANVOORHEES, L ;
GOURLEY, LA ;
JOLLY, MK .
NEW ENGLAND JOURNAL OF MEDICINE, 1993, 329 (01) :1-7
[10]  
Perry G, 1997, NEW ENGL J MED, V336, P525